|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bipolar Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Disease | |||||
| 3 | More general conditions related to this trial | ||||
| Affective Disorders, Psychotic | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| Lithium Carbonate | |||||
| Optimized Treatment (OPT) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Lithium | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antidepressive Agents | |||||
| Antimanic Agents | |||||
| Antipsychotic Agents | |||||
| Central Nervous System Agents | |||||
| Central Nervous System Depressants | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Therapeutic Uses | |||||
| Tranquilizing Agents | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||